


### Attendees Question and Voting Process. V





### Meeting Agenda. V

#### **Business of the Meeting**

#### Chairperson's Address

Tony Offen

#### Chief Executive Officer's Address

Brian Watson

#### **Ordinary Resolutions**

- Re-election of Geoff Plunket as a director
- Re-election of Barry Richardson as a director
- Directors authorised to fix the auditors remuneration



Other Business



# Board of Directors. ¥



Anthony (Tony) Offen

Chair, Independent

non-executive director



Geoffrey Plunket

Independent non-executive director

Chair of Audit and Risk Committee



Dr Alison Stewart

Independent non-executive director
Chair of Remuneration Committee



Antony (Tony) Balfour

Independent

non-executive director



Dr Barry Richardson

Independent non-executive director

Member of Audit Committee



### Disclaimer. V

#### Information

The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of Blis Technologies Limited ("Company" or "Blis"). The information in this presentation is of a general nature and does not purport to be complete. This presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements, which are available at nzx.com.

#### Not financial product advice

This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire Blis securities, and has been prepared without taking into account the objectives, financial situation or needs of individuals. The Company, its directors and employees do not give or make any recommendation or opinion in relation to acquiring or disposing of shares.

In making an investment decision, investors must rely on their own examination of the Company, including the merits and risks involved. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any acquisition of securities.

#### Future performance

This presentation may contain certain 'forward-looking statements', for example statements concerning the development and commercialisation of new products, regulatory approvals, customer adoption and results of future clinical studies. Forward-looking statements can generally be identified by the use of forward-looking words such as, 'expect', 'anticipate', 'likely', 'intend', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance' and other similar expressions. The forward-looking statements contained in this presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of the Company and may

involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not materially differ from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to the Company as at the date of this presentation.

Except as required by law or regulation (including the NZX Main Board Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.


#### No representation

This presentation may contain information from third-parties believed to be reliable, however, no representations or warranties are made as to the accuracy or completeness of such information.




### Results FY 21. V

#### Revenue (NZ\$m)



#### EBITDA (NZ\$m)







Probi. ¥

July, 2021



# CEO Address. ¥

**Brian Watson** 

Chief Executive Officer (CEO)





### The BLIS Leadership Team. ¥



Brian Watson
Chief Executive Officer (CEO)



Richard Wingham

Chief Financial Officer (CFO)



Julie Curphey
Chief Marketing Officer (CMO)



Dr John Hale
Chief Technology Officer (CTO)



Frank Spiewack

Commercial Director




Laura Grant
e-Commerce Director




### FY21 summary. V


#### Revenue (NZ\$m)



#### EBITDA (NZ\$m)



#### FY21 Revenue (NZ\$m)





### FY21 summary.

### New market developments:

- » Canada launch
- » CBEC Tmall Flagship store launch



### New probiotic strain and new product launch

- » Commercial release of BLIS Q24™
- » Launch of Unconditional Skincare Co. brand and the Live Probiotic Hydration Serum



#### Regulatory approvals

- » Finalised Health Canada approvals for BLIS® finished products, with strong health benefit claims
- » BLIS K12<sup>™</sup> and BLIS M18<sup>™</sup> approval in India



#### Capability build and key new hires

» E-commerce, Marketing, Sales



### Q1 update. ¥

>> Unaudited results for the quarter ending 30 June 2021 (Q1 FY22)

Revenue and EBITDA are in-line with our expectations

\$1.8m

Total revenue for the quarter

\$1.2m

### Outlook.¥

- » We remain confident of delivering revenue growth in the current financial year
- » Meaningful longer-term growth and value creation requires ongoing investment upfront
- » The additional opportunities represented by our Probi partnership will be assessed in the next few months.



### Our purpose. V

Developing breakthrough probiotic solutions for the health and wellbeing of global consumers. Core branded revenue streams







Innovation through R&D





# Strategic focus and growth agenda. ¥

#### Strategic priorities:

#### Build our branded finished product e-commerce sales presence.

- » Priority markets: Australasia, USA, China Cross-Border e-commerce (CBEC), Canada
- » Supported by retail in NZ, Australia, Canada

#### Three health and wellness targets

- » ENT/ Immunity
- » Dental Health
- » Skincare

#### Targeted ingredient activity to drive scale

- » Prioritised markets: USA, Japan, China
- » Broad market penetration through the Probi relationship

#### Invest in our pipeline


» Strong investment in R&D, new product development and IP protection





### Addressable markets. V

#### Global Probiotic Supplements Market Revenue



Source: Euromonitor International – IPA Global Probiotics Annual Market Report

1. Passport - World Market for Beauty and Personal Care, September 2020: Euromonitor International
2. Global Skin Microbiome Modulators Market: Focus on Products, Applications, Distribution Channels, Country Data (14 Countries), and
Competitive Landscape - Analysis and Forecast, 2019-2030: Research and Markets



### Probi strategic partnership. V

#### Additional growth pathway

Establishment of a licence and supply agreement to drive increased revenue

» Blis grants Probi the right to manufacture and sell BLIS K12™, BLIS M18™ as ingredients and finished products and the opportunity to collaborate on future products.

Collaboration in R&D to leverage joint strengths in probiotic innovation

Strategic investment by Probi of \$9.18m enhancing the Blis capital position

» Providing Blis with capital to support revenue growth initiatives





### Probi in brief

Probi AB is a Swedish listed biotechnology company.

#### One of the largest, leading probiotic companies in the world

Probi was founded by researchers in Lund in 1991. Today we are one of the largest and leading global probiotic companies with a total of four units in the USA, Sweden and Singapore. Probi has a strong and broad product portfolio, primarily in the areas of digestive health and the immune system.

#### Own fermentation and production

Probi has its own capacity for fermentation, formulation and production, which are conducted in GMP certified facilities. Probi develops, manufactures, markets and sells probiotics in the form of powder, capsules, tablets or food in close collaboration with leading health, pharmaceutical and food companies.

#### Commercial research

Probi is a leader in innovation and development and invests large resources in commercially-based and structured research and development. All projects are based on customer needs. In recent years, Probi has presented a number of studies with findings that are important for Probi's future development. Probi has over 400 patents worldwide.

#### **Our vision** Probi aspires to be the innovative frontrunner within probiotics. Our ambition is to improve the well-being of people worldwide. This is what drives and inspires us. Our mission Providing probiotics for healthier lives worldwide. Millions of people suffer from health issues that can benefit from careful addition of probiotics. At Probi, our mission is to provide high-quality probiotics, backed by science, grown with care and manufactured into novel forms. This is how we make life healthier for consumers worldwide.







#### A leading global probiotic company

176
At the end of 2020
Probi had 176
employees.

>40

Probis products are sold in i over 40 countries and more countries are continually being added.

+400

Probi has over 400 patent worldwide.

**REDMOND** ermentation

**LAFAYETTE**Manufacturing
and packaging

Americas Region

**79%** of net sales 2020

EMEA Region

**15%** of net sales 2020

APAC Region

6% of net sales 2020





### Probi. ¥

A word from Probi CEO, Tom Rönnlund



# Scope of collaboration – delivering significant value. ¥

#### Primary opportunities:



#### Blis

- Substantial revenue growth and increased market penetration
- Capital funds of \$9.18m for investment in growth initiatives



#### Probi

An expanded portfolio to sell to a strong existing customer base

#### **Broader opportunities:**

- R&D shared expertise to develop innovative probiotic solutions
- Scientific and clinical validation of probiotic health benefits
- Contract manufacture both fermentation and finished product manufacture providing operational synergies
- Opportunities for cross licensing of Probi strains to expand the Blis finished product portfolio

### Use of the capital funds. V

### Accelerate our growth priorities

- Skincare launch activity
- D2C e-commerce investment: USA, CBEC, Australasia, Canada
- Canada launch activity

#### Pipeline investment

- New product development acceleration.
- New strain development

### Internal capability investment

 Marketing and e-commerce focus





### New market and product initiatives. ¥






# Skincare product launch. ¥



### **Unconditional** Skincare Co.<sup>®</sup>

Skin peace for all









### Breakthrough innovation. >

Blis' Addressable Market: Premium Skincare

Competitive advantage: Breakthrough innovation

The skincare market: high engagement, and consumers are willing to pay for breakthrough innovation.

> Global skin microbiome modulators market to reach US\$2.97 billion

#### From the Skin for the Skin

The unique patented probiotic originates from the skin microbiome so colonises harmoniously with your skin

No nasty chemicals, no animal testing just friendly naturally occurring bacteria

Strengthens your skin's barrier preventing future breakouts

Clearer and healthier skin noticed in just 10 days

Hydrates the skin

Live Probletic Hydration Serum

1024

Live probiotic actively works to inhibit bad bacteria and balance your microbiome





## Influencer engagement. >













### Customer reviews. >



"My skin is smoother, much brighter, healthier and aone is reduced significantly."

- Nadia



"This serum has transformed my skin and this is no exaggeration.

My skin looks thicker and stronger and the adult acne breakouts I've had throughout adulthood have all but gone. I cannot recommend this serum enough."

- Claire



"It's become my skincare staple. It sounds odd but my skin feels so much stronger, so when I do experience some hormonal acne it clears up quickly. And best of all I've received SO many compliments about my skin..."

- Marie

"I've been really pleased with the results - skin is looking much clearer. I've had issues with acne and redness throughout the years. Will be buying a second bottle."

- Campbell





### Canada. V

>> Represents an important new market with significant and attractive claim opportunities

#### >> Omni channel focus

- e-commerce sales activity
- Retail sales activity with Purity Life









### CBEC. V

- >>> BLIS PROBIOTICS™ Tmall Flagship store launched Jan 2021
- >> Heavy focus on building our brand presence through digital marketing social media and influencer activity
- >> Reseller / Daigou activity remains a contributor but not a primary focus based on challenges in this segment







### R&D and NPD pipeline investment. ¥

#### >> NPD

- **Dental:** Late-stage probiotic toothpaste development
- **Skincare:** Additional skincare and personal care targets
- **ENT/ Immunity:** Kids focus
- Blis range extension utilising Probi innovation

#### >> New strain development

 Unlock the vault (Blis strain library) – rapid screening and characterisation

#### >> New IP generated

#### >> Probi collaboration

- Combining innovation strengths
- Extended use of Blis strains into new areas including combinations
- Scientific and clinical validation of probiotic health benefits



### People and Performance. >

#### Key new hires



e-commerce Director



Category Manager ENT/ Immunity



Category Manager Skin



Global Ingredients and Private Label Account Manager



People and Culture Manager



Op St

Operations and Supply Chain Manager

#### **Process**

- Refreshed company values
- Execution focus Faster and Smarter
- Sustainability focus
- Digital strategy and knowledge management
- Cyber security enhancements



### Sustainability. V

#### Our Sustainability priorities are linked to the UN Sustainability Goals

Advance Health & Wellbeing

- Access products
- Focus on quality
- Staff wellbeing











Contribution to Society

- Economic contribution
- Support of charities and sponsorship
- Staff policies: living wage, diversity, development









**Environmental Impact** 

- Understanding of footprint
- Areas of greatest relevance supply chain, packaging
- · Leading behaviour change





Contribute to an innovation economy

- World leading science
- Research and academic support
- Innovative product export earnings













### Green lab certification. V

my green lab certification.

Blis is proud to be the **first NZ based lab** to complete this international certification achieving the highest level of certification.

#### **Topics Covered**

Our green lab certification program covers 14 topics related to energy, water, waste, chemistry/materials and engagement.



Infrastructure Energy



Plug Load



Fume Hoods



Large Equipment



Cold Storage



Water



Purchasing



Resource Management



Green Chemistry and Green Biologics



Recycling & Waste Reduction



Vivaria



Field Work



Travel



Community

Congratulations on achieving your green lab certification!!
The lab did an incredible job and should be very proud of their accomplishment. I have attached your feedback report, the lab scored an 86% overall and achieved the highest certification level!



### Summary. V












### Questions.\*

#### Wait for the microphone






### Attendees Question Process. V






### Resolutions.¥

#### Wait for the microphone





### Attendees Voting Process. V





### Resolution 1. ¥

That Mr Geoffrey Plunket be elected as a director of the Company.

#### Wait for the microphone





### Resolution 2.

That Dr Barry Richardson be elected as a director of the Company.

#### Wait for the microphone





### Resolution 3.¥

That the Directors be authorised to fix the remuneration of the auditors for the ensuing year.

#### Wait for the microphone



# General Business.¥

